Axxam is a member of the REsolution consortium

Axxam announces its participation in the REsolution consortium, a public-private research partnership supported by the Innovative Medicines Initiative (IMI), to accelerate research in the field of solute carrier (SLC) class of transporters.

Axxam acquires Hit Discovery Constance

Axxam is proud to announce the entire acquisition of the share capital of Hit Discovery Constance GmbH (“HDC”). As a consequence, HDC founded in 2014 as a joint venture between Axxam, Centre for Drug Design and Discovery of KU Leuven and Lead Discovery Center GmbH, is now a subsidiary of Axxam.

Symegold library for drug discovery services

Thanks to the long-standing collaboration with Symeres (recently rebranded from MercachemSyncom), Axxam has access to an additional library of approx. 80,000 lead-like compounds synthetized at Symeres, named Symegold library, for use in high-throughput screens.

Scroll to Top